AR046616A1 - Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico - Google Patents
Piperidinas sustituidas utiles en el tratamiento de sindrome metabolicoInfo
- Publication number
- AR046616A1 AR046616A1 ARP040104087A ARP040104087A AR046616A1 AR 046616 A1 AR046616 A1 AR 046616A1 AR P040104087 A ARP040104087 A AR P040104087A AR P040104087 A ARP040104087 A AR P040104087A AR 046616 A1 AR046616 A1 AR 046616A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- amino
- carbamoyl
- heterocyclyl
- sulfamoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Reivindicación 13: Un compuesto caracterizado porque responde a la fórmula (1), en donde: El anillo A se selecciona entre fenilo, piridilo, tienilo, furilo o tiazolilo; R1 es un sustituyente sobre carbono y se selecciona entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C1-4 alcoxi, C1-4 alcanoilo, C1-4 alcanoiloxi, N-(C1-4 alquil)amino, N,N-(C1-4 alquil)2amino, C1-4 alcanoilamino, N-(C1-4 alquil)carbamoilo, N,N- (C1-4 alquil)2carbamoilo, C1-4alquil(SO)a en donde a es entre 0 y 2, C1-4 alcoxicarbonilo, N-(C1-4 alquil)sulfamoilo, N,N-(C1-4 alquil)2sulfamoilo, C1-4 alquilsulfonilamino, carbociclilo, heterociclilo; en donde R1 pueden ser opcionalmente sustituidos sobre carbono por uno o más grupos seleccionados entre R3; y en donde si dicho heterociclilo contiene una porción -NH- dicho nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R4; n es 0-5; en donde los valores de R1 pueden ser iguales o diferentes; X es a -C(O)-, -S(O)2-, -C(O)NR11-, -C(S)NR11-, -C(O)O-, o -C(=R11)-; en donde R11 se selecciona entre hidrógeno, C1-4 alquilo, carbociclilo y heterociclilo; Y es C1-6 alquilo, C2-6 alquenilo, C2-6 alquinilo, carbociclilo o heterociclilo; en donde Y puede ser opcionalmente sustituido sobre carbono por uno o más R2; en donde si dicho heterociclilo contiene una porción -NH- dicho nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R5; R2 es un sustituyente sobre carbono y se selecciona entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, trifluorometilo, trifluorometoxi, C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C1-4 alcoxi, C1-4 alcanoilo, C1-4 alcanoiloxi, N-(C1-4 alquil)amino, N,N-(C1-4 alquil)2amino, C1-4 alcanoilamino, N-(C1-4 alquil)carbamoilo, N,N-(C1-4 alquil)2carbamoilo, C1-4alquil(SO)a en donde a es entre 0 y 2, C1-4 alcoxicarbonilo, C1-4 alcoxicarbonilamino, C1-4 alcoxicarbonil-N-(C1-4 alquil)amino, N-(C1-4 alquil)sulfamoilo, N,N-(C1-4 alquil)2sulfamoilo, C1-4 alquilsulfonilamino, aminotiocarboniltio, N-(C1-4 alquil)aminotiocarboniltio, N,N-(C1-4 alquil)2aminotiocarboniltio, carbociclilo o heterociclilo; en donde R2 pueden ser opcionalmente sustituidos sobre carbono por uno o más grupos seleccionados entre R6; y en donde si dicho heterociclilo contiene una porción -NH- dicho nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R7; R3 y R6 se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, trifluorometilo, trifluorometoxi, C1-4 alquilo, C2-4 alquenilo, C2-4 alquinilo, C1-4 alcoxi, C1-4 alcanoilo, C1-4 alcanoiloxi, N-(C1-4 alquil)amino, N,N-(C1-4 alquil)2amino, C1-4 alcanoilamino, N-(C1-4 alquil)carbamoilo, N,N-(C1-4 alquil)2carbamoilo, C1-4alquil(SO)a en donde a es entre 0 y 2, C1-4 alcoxicarbonilo, C1- 4 alcoxicarbonilamino, C1-4 alcoxicarbonil-N-(C1-4 alquil)amino, N-(C1-4 alquil)sulfamoilo, N,N-(C1-4 alquil)2sulfamoilo, C1-4 alquilsulfonilamino, carbociclilo o heterociclilo; en donde R3 y R6 pueden estar sustituidos en forma independiente sobre carbono por uno o más R8; y en donde si dicho heterociclilo contiene una porción -NH- dicho nitrógeno puede estar opcionalmente sustituido por un grupo seleccionado entre R13; R4, R5, R7 y R13 se seleccionan en forma independiente entre C1-4 alquilo, C1-4 alcanoilo, C1-4 alquilsulfonilo, C1-4 alcoxicarbonilo, carbamoilo, N-(C1-4 alquil)carbamoilo, N,N-(C1-4 alquil)2carbamoilo, bencilo, benciloxicarbonilo, benzoilo y fenilsulfonilo; R8 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N-etilamino, acetilamino, N-metilcarbamoilo, N- etilcarbamoilo, N,N-dimetilcarbamoilo, N,N-dietilcarbamoilo, N-metil-N-etilcarbamoilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N-metilsulfamoilo, N-etilsulfamoilo, N,N- dimetilsulfamoilo, N,N-dietilsulfamoilo o N-metil-N-etilsulfamoilo; R12 es hidroxi, metilo, etilo, propilo o trifluorometilo; m es 0 ó 1; q es 0 ó 1; o una sal aceptable para uso farmacéutico de los mismos; con la salvedad de que dicho compuesto no sea: 1-acetil-3-(4-fluorobenzoil)piperidina; 1-acetil-3-(4-dimetilaminobenzoil)piperidina; 1-(4-nitrobenzoil)-3-(4-fluorobenzoil)piperidina; 1-(4-aminobenzoil)-3-(4-fluorobenzoil)piperidina; 1-acetil-3-(4-ftalimidobenzoil)piperidina; 1-(benzoil)-3- (4-mesilaminobenzoil)piperidina; 1-(t-butoxicarbonil)-3-(4-aminobenzoil)piperidina; o 1,3-dibenzoilpiperidina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0326029.6A GB0326029D0 (en) | 2003-11-07 | 2003-11-07 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR046616A1 true AR046616A1 (es) | 2005-12-14 |
Family
ID=29726142
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040104087A AR046616A1 (es) | 2003-11-07 | 2004-11-05 | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070112000A1 (es) |
EP (1) | EP1684757A1 (es) |
JP (1) | JP2007510703A (es) |
CN (1) | CN1901910A (es) |
AR (1) | AR046616A1 (es) |
GB (1) | GB0326029D0 (es) |
TW (1) | TW200524867A (es) |
UY (1) | UY28603A1 (es) |
WO (1) | WO2005046685A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
WO2006074330A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
BRPI0606256A2 (pt) | 2005-01-05 | 2009-06-09 | Abbott Lab | inibidores da enzima 11-beta-hidroxiesteróide desidrogenase tipo i, uso e composição farmacêutica compreendendo os mesmos |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
EP1866298A2 (en) | 2005-03-31 | 2007-12-19 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
AU2007207055B2 (en) | 2006-01-18 | 2011-06-02 | F. Hoffmann-La Roche Ag | Thiazoles as 11 beta-HSD1 inhibitors |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
GB0724251D0 (en) | 2007-12-12 | 2008-02-06 | Univ Edinburgh | Therapeutic compounds and their use |
GB0804685D0 (en) | 2008-03-13 | 2008-04-16 | Univ Edinburgh | Therapeutic compounds and their use |
TW200944526A (en) | 2008-04-22 | 2009-11-01 | Vitae Pharmaceuticals Inc | Carbamate and urea inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
US20100022572A1 (en) | 2008-07-18 | 2010-01-28 | Kowa Company, Ltd. | Novel spiro compound and medicine comprising the same |
JP5574431B2 (ja) | 2008-08-29 | 2014-08-20 | 興和株式会社 | 1−アダマンチルアゼチジン−2−オン誘導体及びこれを含有する医薬 |
WO2010050191A1 (ja) | 2008-10-29 | 2010-05-06 | 興和株式会社 | 1,2-ジアゼチジン-3-オン誘導体及びこれを含有する医薬 |
ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
CA2772504C (en) | 2009-09-16 | 2017-10-24 | The University Of Edinburgh | (4-phenyl-piperidin-1-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use |
EP2563780B1 (en) | 2010-04-29 | 2015-05-06 | The University Of Edinburgh | 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1 |
PT2968316T (pt) | 2013-03-13 | 2019-10-29 | Forma Therapeutics Inc | Derivados de 2-hidroxi-1-{4-[(4-fenilfenil)carbonil]piperazin-1-il}etano-1-ona e compostos relacionados como inibidores da sintase de ácidos gordos (fasn) para o tratamento do cancro |
KR20180017013A (ko) * | 2015-05-06 | 2018-02-20 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | K-Ras 조절제 |
EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
EP3375778A1 (en) * | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
AU2018255413A1 (en) | 2017-04-20 | 2019-12-05 | Leidos Biomedical Research, Inc. | K-Ras modulators |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8401092D0 (en) * | 1984-01-16 | 1984-02-15 | Fujisawa Pharmaceutical Co | Piperidine derivatives |
JP2969359B2 (ja) * | 1989-01-13 | 1999-11-02 | 武田薬品工業株式会社 | 環状アミン化合物 |
CA2386474A1 (en) * | 1999-09-20 | 2001-03-29 | Takeda Chemical Industries, Ltd. | Melanin concentrating hormone antagonist |
JP4368683B2 (ja) * | 2002-02-01 | 2009-11-18 | メルク エンド カムパニー インコーポレーテッド | 糖尿病、肥満症および脂質代謝異常の治療に有用な11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1阻害剤 |
EA200400980A1 (ru) * | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
AU2003269242A1 (en) * | 2002-10-11 | 2004-05-04 | Astrazeneca Ab | 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors |
DE602004027171D1 (de) * | 2003-04-11 | 2010-06-24 | High Point Pharmaceuticals Llc | Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase |
-
2003
- 2003-11-07 GB GBGB0326029.6A patent/GB0326029D0/en not_active Ceased
-
2004
- 2004-11-04 US US10/578,444 patent/US20070112000A1/en not_active Abandoned
- 2004-11-04 JP JP2006538923A patent/JP2007510703A/ja not_active Withdrawn
- 2004-11-04 WO PCT/GB2004/004650 patent/WO2005046685A1/en not_active Application Discontinuation
- 2004-11-04 EP EP04798379A patent/EP1684757A1/en not_active Withdrawn
- 2004-11-04 CN CNA200480039774XA patent/CN1901910A/zh active Pending
- 2004-11-05 AR ARP040104087A patent/AR046616A1/es unknown
- 2004-11-05 TW TW093133932A patent/TW200524867A/zh unknown
- 2004-11-05 UY UY28603A patent/UY28603A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007510703A (ja) | 2007-04-26 |
EP1684757A1 (en) | 2006-08-02 |
UY28603A1 (es) | 2005-06-30 |
CN1901910A (zh) | 2007-01-24 |
TW200524867A (en) | 2005-08-01 |
US20070112000A1 (en) | 2007-05-17 |
GB0326029D0 (en) | 2003-12-10 |
WO2005046685A1 (en) | 2005-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR046616A1 (es) | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico | |
AR046615A1 (es) | Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos | |
AR041594A1 (es) | Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1 | |
AR055249A1 (es) | Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas | |
AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
AR056210A1 (es) | 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa | |
AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
AR056556A1 (es) | Imidazo(1,2-a)piridina con actividad antiproliferacion celular | |
AR056184A1 (es) | Compuestos derivados de pirazol, composicion farmaceutica en base a aquellos y su uso para la fabricacion de medicamentos | |
AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
AR053683A1 (es) | Derivados de piperidina con actividad antibacteriana | |
AR064208A1 (es) | Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas. | |
AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
AR061653A1 (es) | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) | |
AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
AR033836A1 (es) | Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion | |
AR052170A1 (es) | Derivados de pirimidina utiles por su actividad anti-proliferacion celular | |
AR056354A1 (es) | DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO | |
AR064130A1 (es) | Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas. | |
AR031251A1 (es) | Derivado de pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento y proceso de preparacion | |
AR040409A1 (es) | Inhibidores de histona desacetilasa | |
AR066977A1 (es) | Compuestos de piperidina y usos de los mismos | |
AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
AR037487A1 (es) | Compuestos derivados de pirimidina, proceso para prepararlos, composicion farmaceutica y el uso de los mismos en la fabricacion de medicamentos que producen un efecto inhibidor del ciclo celular (anti-proliferacion celular) | |
ATE524476T1 (de) | Pyrazolopyrimidine als modulatoren von caseinkinase ii (ck2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |